Drug Master File (DMF)

What it is

Drug Master File (DMF) is a confidential submission to FDA that describes facilities, processes, and materials used in the manufacturing, processing, packaging, or storing of drugs. A DMF is not an approval; FDA references it—via a sponsor’s Letter of Authorization (LOA)—to support INDs, NDAs, ANDAs, or other applications (21 CFR 314.420). DMFs help protect proprietary know-how while enabling regulators to review quality and compliance.

Regulatory framework

• Legal basis: Content, format, and maintenance per 21 CFR 314.420 and FDA guidance (eCTD format required for most DMFs supporting applications).
• Types: Type II (drug substance/intermediates/DS facilities), Type III (packaging materials), Type IV (excipients, colorants, flavors, essences), Type V (FDA-accepted reference information). Type I is obsolete.
• Use: Referenced by LOA in IND/NDA/ANDA; FDA reviews only in the context of an application.
• User fees/inspection: Type II API DMFs that support ANDAs fall under GDUFA expectations, including facility self-identification and possible inspections.

Key elements

• Administrative data: Holder, DMF number, type, sites, contacts, LOA tracking.
• Quality dossier: Manufacturing process, controls, specifications, analytical methods/validation, stability, packaging (as applicable).
• Facilities & equipment: GMP controls, cleaning/validation, HVAC/water systems, data integrity.
• Change management: Amendment strategy and notification commitments to affected applicants.
• Status control: Active, inactive, or closed; yearly update letters to maintain status.

Process — how it works

• 1) Decide scope & type: Pick the correct DMF type (II/III/IV/V) and align with the supporting applications.
• 2) Prepare dossier: Author in eCTD with complete manufacturing/controls, site details, and stability or packaging data.
• 3) Submit to FDA: Obtain DMF number; respond to FDA information requests (if referenced).
• 4) Issue LOAs: Send Letters of Authorization to each sponsor so FDA can reference the DMF in their IND/NDA/ANDA.
• 5) Maintain: File annual reports, amendments for changes, and promptly inform all authorized sponsors.
• 6) Monitor outcomes: Address deficiency letters routed via the referencing application; keep alignment with GMP and data integrity expectations.

Common pitfalls

• Submitting a DMF in the wrong type or without full site/process scope.
• Insufficient analytical method validation or incomplete stability data.
• Poor change control and delayed notification to authorized sponsors.
• Letting the DMF lapse (no annual report) or mismanaging LOA tracking.
• Data-integrity gaps (incomplete contemporaneous records, missing audit trails).

Quick checks / Tips

• Does the eCTD include complete process flow, controls, specs, and method validation?
• Are all manufacturing and testing sites listed and GMP-ready?
• Have you logged every LOA and notified each sponsor of amendments?
• Is the annual report current and does it summarize all changes since last update?